http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2182369-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01f30eff2b6b2f7fe6bd19be99c85ee8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G09B23-28 |
| filingDate | 2000-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05b2000bd657c009095580ce10bbc44d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b90236a4725046a242a4c9007e6d34f8 |
| publicationDate | 2002-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2182369-C2 |
| titleOfInvention | Method for modeling proliferative vitreoretinopathy |
| abstract | FIELD: medicine. SUBSTANCE: method involves administering cellular elements suspension with physiological salt solution into the vitreous body with histologic study of serial eyeball slices. Blood mononuclear cells are used as the cellular elements. Indirect ophthalmoscopy and histologic study at the first, third, fifth, seventh, fourteenth, twenty first day are carried out for making control. Model construction is proved to take place from development of massive vitreoretinal membranes. EFFECT: enhanced accuracy of the method; accelerated model production. 10 dwg |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2568368-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2498415-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2563368-C1 |
| priorityDate | 2000-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.